Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis
Open accessThe DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Abstract
Currently, the treatment for ocular neovascular diseases, including diabetic macular edema (DME) and age-related macular degeneration (AMD), mainly involves repeated intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs. Although it can preserve vision, repeated injections are an invasive treatment modality, leading to serious complications and reducing patient adherence to treatment. To reduce the frequency of administration, prolong the time of drug action, and avoid repeated intravitreal injections, the combination of sustained-release materials with anti-VEGF drug therapy has become an emphasis in ophthalmology. In this review, we highlight the current state of anti-VEGF technology, its challenges, and the sustained-release strategies under investigation or being used in clinical practice. Both continuous release and considerable therapeutic effects can be achieved by encapsulating anti-VEGF drugs in sustained-release materials to minimize the number of intravitreal injections. At present, two sustained-release materials are being tested in clinical research, and although basic research shows the strong therapeutic application prospects of extended-release drugs, its challenges mainly involve the discrepancy between the release rates in vitro and the efficiency of the drugs in vivo. Briefly, sustained release of anti-VEGF agents is an advantageous strategy for treating retinal angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“VEGF is a key mediator of the pathological angiogenesis and the formation of macular choroidal neovascularisation (CNV) that, without intervention, is directly responsible for vision loss in nAMD.2,4,5,7”
From Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aflibercept is an anti-VEGF recombinant fusion protein, which was FDA approved for nAMD in 2011 and has been administered intravitreally over 20 million times worldwide to treat VEGF-mediated retinal disorders.3,7”
From Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, repeated intravitreal injections are invasive and risk potentially blinding complications (18).”
From Characterization of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331
Self-citationDe Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,136
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Cheung, N., Mitchell, P., & Wong, T. Y. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62124-3 · Cited by 3,288
Polymeric systems for controlled drug release
Uhrich, K. E., Cannizzaro, S. M., Langer, R. S., & Shakesheff, K. M. (1999) · Chemical Reviews · doi:10.1021/cr940351u · Cited by 2,633 · cited 1×
“PLGA can be processed into virtually any shape and size, can encapsulate molecules of virtually any size, and is soluble in a variety of common solvents, including chlorinated solvents, tetrahydrofuran, acetone, and ethyl acetate.(109,110) In water, PLGA is biodegraded by the hydrolysis of ester bonds.”
BackgroundIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485 · cited 2×
“Some studies have shown that delaying or reducing the number of injections can lead to varying degrees of vision loss.(55,73) The use of anti-VEGF drugs has changed the outlook for patients with retinal vascular diseases.”
BackgroundMethodChitosan-based hydrogels for controlled, localized drug delivery
Bhattarai, N., Gunn, J., & Zhang, M. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.07.019 · Cited by 2,451
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Jain, R. A. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00115-0 · Cited by 2,214
Research works printed but not linked: 13
- Domańska-Janik, 1972, Neuropatol Pol, 10, 17
- Kim, 2018, Surv Ophthalmol, 63, 618, 10.1016/j.survophthal · doi:10.1016/j.survophthal
- Ferrara, 2006, Retina, 26, 859, 10.1097/01.iae.0000242842 · doi:10.1097/01.iae.0000242842
- Arrigo, 2021, Pharmaceutics, 13, 10.3390/pharmaceutics.13071102 · doi:10.3390/pharmaceutics.13071102
- Zhang, 2008, Mol Vis, 14, 37
- Chandrasekaran, 2021, Ther Adv Ophthalmol, 13, 25158414211027708, 10.1177/251.58414211027708 · doi:10.1177/251.58414211027708
- Liang, 2018, Invest Ophthalmol Vis Sci, 59, 211
- 2020, Angiogenesis, Exudation and Degeneration, 8 February 2020
- Tseng, 2012, J Glaucoma, 21, 241, 10.1097/ijg.0b013e31820.d7d19 · doi:10.1097/ijg.0b013e31820.d7d19
- Mouallem, 2016, Retina, 36, 2197, 10.1097/iae.0000.000000001062 · doi:10.1097/iae.0000.000000001062
- 2019, Hawaiian Eye & Retina Annual Meeting, January 21, 2019
- Pandit, 2017, Artif Cells Nanomed Biotechnol, 45, 1397, 10.1080/21691401.20161243545 · doi:10.1080/21691401.20161243545
- Nadarassan, 2014, Invest Ophthalmol Vis Sci, 55, 1950
Cited by
Bahr, T. A., & Bakri, S. J. (2023) · Life · doi:10.3390/life13051098 · Cited by 114
Srejovic, J., Muric, M. D., Jakovljevic, V. L., Srejovic, I. M., Srećković, S., Petrovic, N. T., Todorović, D., Bolevich, S., & Šarenac-Vulović, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111850 · Cited by 89
Khanani, A. M., Boyer, D. S., Wykoff, C. C., Regillo, C. D., Busbee, B. G., Pieramici, D., Danzig, C. J., Joondeph, B. C., Major, J. C., Turpcu, A., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102394 · Cited by 76
Vascular Endothelial Growth Factor (VEGF) and Its Role in the Cardiovascular System
Florek, K., Mendyka, D., & Gomułka, K. (2024) · Biomedicines · doi:10.3390/biomedicines12051055 · Cited by 60
Smart molecules in ophthalmology: Hydrogels as responsive systems for ophthalmic applications
Kulbay, M., Wu, K. Y., Truong, D., & Tran, S. D. (2024) · Smart Molecules · doi:10.1002/smo.20230021 · Cited by 49
Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives
Gacche, R. N. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189020 · Cited by 43
Diabetic retinopathy: a comprehensive review of pathophysiology and emerging treatments
Shyam, M., Sidharth, S., Veronica, A., Jagannathan, L., Srirangan, P., Vidya, R., & Prince, S. E. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10490-7 · Cited by 39
Recent advances in engineered exosome-based therapies for ocular vascular disease
Guan, J., Meng, F., Wang, C., Zhang, B., Chen, J., & Han, J. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03589-3 · Cited by 36
The β3 adrenoceptor in proliferative retinopathies: “Cinderella” steps out of its family shadow
Cammalleri, M., Amato, R., Monte, M. D., Filippi, L., & Bagnoli, P. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106713 · Cited by 32
Aldokhail, L., Alhadlaq, A., Alaradi, L. M., ALAradi, D. L., & AlShaikh, F. Y. (2024) · Clinical ophthalmology · doi:10.2147/opth.s489114 · Cited by 28
Patel, S. S., Storey, P. P., Barakat, M., Hershberger, V. S., Bridges, W. Z., Eichenbaum, D. A., Lally, D. R., Boyer, D. S., Bakri, S. J., Roy, M., et al. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100527 · Cited by 26
Advancements in hydrogel technology for ocular drug delivery
Truong, D., Wu, K. Y., Nguyen, L., & Tran, S. D. (2024) · Exploration of BioMat-X · doi:10.37349/ebmx.2024.00023 · Cited by 24
Abbasi, M., Aghamollaei, H., Vaez, A., Amani, A. M., Kamyab, H., Chelliapan, S., Jamalpour, S., & Zambrano-Dávila, R. (2025) · The Ocular Surface · doi:10.1016/j.jtos.2025.03.004 · Cited by 23
Characterization of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina
Kumar, S., Hsiao, Y.-W., Wong, V. H. Y., Aubin, D., Wang, J.-H., Lisowski, L., Rakoczy, E. P., Li, F., Alarcon-Martinez, L., Gonzalez-Cordero, A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2408345121 · Cited by 19
Chen, K.-Y., Chan, H.-C., & Chan, C.-M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118881 · Cited by 25
PFKFB3 in neovascular eye disease: unraveling mechanisms and exploring therapeutic strategies
Liu, P., Sun, D., Zhang, S., Chen, S., Wang, X., Li, H., & Fang, W. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01205-9 · Cited by 19
Moyo, M. T. G., Adalı, T., & Tulay, P. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.05.018 · Cited by 17
Yao, J., Huang, W., Gao, L., Liu, Y., Zhang, Q., He, J., & Zhang, L. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304283 · Cited by 16
Fu, S., Sun, W., Liu, L., Xiao, J., Xiong, J. P., Hu, Y., Zhou, Q., & Yin, X. (2024) · Diabetes · doi:10.2337/db23-1015 · Cited by 19
Natural remedies proposed for the management of diabetic retinopathy (DR): diabetic complications
Khidr, E. G., Morad, N. I., Hatem, S., El‐Dessouki, A. M., Mohamed, A. F., El‐Shiekh, R. A., Hafeez, M. S. A. E., & Ghaiad, H. R. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03866-w · Cited by 18
Choi, A. Y., Nawash, B. S., Du, K., Ong, J., & Chhablani, J. (2023) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2023.09.001 · Cited by 14
Bond-Centric Modifications of Hyaluronic Acid: Synthesis, Processing, and Biomedical Applications
Yang, A., Yang, P., Shen, N., Wu, R., Liu, X., Ju, Y., Lei, L., & Fang, B. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s560798 · Cited by 13
Khalili, H., Kashkooli, H. H., Weyland, D. E., Pirkalkhoran, S., & Grabowska, W. R. (2023) · Pharmaceuticals · doi:10.3390/ph16040620 · Cited by 13
Inhibition of hypoxia‐inducible factors suppresses subretinal fibrosis
Shoda, C., Lee, D., Miwa, Y., Yamagami, S., Nakashizuka, H., Nimura, K., Okamoto, K., Kawagishi, H., Negishi, K., & Kurihara, T. (2024) · The FASEB Journal · doi:10.1096/fj.202400540rrr · Cited by 15
Li, H., & Huang, X. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12893 · Cited by 15
Identification of Novel Pathways Regulated by APE1/Ref-1 in Human Retinal Endothelial Cells
Mijit, M., Liu, S., Sishtla, K. L., Hartman, G. D., Wan, J., Corson, T. W., & Kelley, M. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021101 · Cited by 11
Gao, S., Lin, Z., Zhong, Y., & Shen, X. P. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm14010018 · Cited by 10
Wang, S., Zhang, J., Chen, J., Tang, L., Ke, M., Xue, Y., He, Y., Gong, Y. Q., & Li, Z. (2024) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04795-1 · Cited by 10
Localised Therapies Using 3D‐Printed Collagen‐Based Micro‐Implant for Ocular Indications
Kashkooli, H. H., Farokh, A., Mohammadi, S., Marcotulli, M., Franco, S., Angelini, R., Ruocco, G., Khalili, H., & Cidonio, G. (2025) · Macromolecular Materials and Engineering · doi:10.1002/mame.202400236 · Cited by 9
Allan, K. C., Cohn, E. F., Bala, S., Kim, S., Kaelber, D. C., Singh, R. P., Talcott, K. E., Mammo, D. A., & Rachitskaya, A. V. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.10.020 · Cited by 15
Lee, D., Fu, Z., Hellström, A., & Smith, L. E. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105503 · Cited by 8
Advancements and emerging trends in ophthalmic anti-VEGF therapy: a bibliometric analysis
Deng, J., & Qin, Y. (2024) · International Ophthalmology · doi:10.1007/s10792-024-03299-z · Cited by 9
Application of Nanomaterials in the Diagnosis and Treatment of Retinal Diseases
Yao, Y., Cao, Q., Fang, H., & Tian, H. (2025) · Small · doi:10.1002/smll.202503070 · Cited by 7
Adak, S., Jadhav, V. S., & Khatri, D. K. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01925-6 · Cited by 11
Ocular Delivery of Viral Vectors for Retinal and Choroidal Vascular Diseases: A Review
Agrawal, R., Oraskovich, S. V., Francis, P. J., & Schaffer, D. V. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.07.025 · Cited by 7
The Antiangiogenic Effect of VEGF-A siRNA-FAM-Loaded Exosomes
Hur, W., Bhujel, B., Oh, S., Lee, S., Chung, H. S., Park, J. H., & Kim, J. Y. (2025) · Bioengineering · doi:10.3390/bioengineering12090919 · Cited by 6
Li, B., Chen, J., Zhu, J., Zhou, H., Zhang, Q., Deng, H., Wen, H., Xu, F., Tang, F., Yoshida, S., et al. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70180 · Cited by 6
Cammalleri, M., Filippi, L., Monte, M. D., & Bagnoli, P. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1408605 · Cited by 6
Choi, J., Shim, S., Shin, J., Lee, A., Strang, J., Braun, T., Naef, R., & Jung, H. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.03.024 · Cited by 18
Anti-neoangiogenic nanodelivery systems: advances in tumor-based and ophthalmic disease research
Guo, B., Li, Z., Zhou, J., Shu, R., Wei, W., Kuang, Y., Xu, Y., & Wu, X. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01502b · Cited by 7
The potential role of adipokines and hepatokines in age-related ocular diseases
Almpanidou, S., Vachliotis, I. D., Goulas, A., & Pοlyzos, S. A. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100365 · Cited by 6
Criscio, A. D., Rosso, P., Fico, E., Iannetta, D., Marenco, M. T. R., Lambiase, A., & Tirassa, P. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04032-4 · Cited by 5
Alshahrouri, B., Blass, B. E., Dürig, T., & Fassihi, R. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01253-8 · Cited by 5
Lin, H., Gao, X., Wu, Z., Tam, W., Huang, W., Dong, Y., Qin, X., Liu, Y., Zuo, C., & Lin, M. (2025) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2025.100136 · Cited by 5
The Long-Standing Problem of Proliferative Retinopathies: Current Understanding and Critical Cues
Cammalleri, M., & Bagnoli, P. (2025) · Cells · doi:10.3390/cells14141107 · Cited by 5
Aflibercept Off-Target Effects in Diabetic Macular Edema: An In Silico Modeling Approach
Blanot, M., Casaroli-Marano, R. P., Mondéjar-Medrano, J., Sallén, T., Ramírez, E., Segú-Vergés, C., & Artigas, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073621 · Cited by 5
Moon, C., Koh, T.-Y., Yoon, J.-S., Kim, M., & Ha, K. (2026) · Cells · doi:10.3390/cells15080689 · Cited by 4
Guo, S., Li, M., Jia, Z., Xu, D., Yu, C., Mei, Y., Zhao, Y., Duan, X., Guo, X., He, P., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125500 · Cited by 3
Ding, S., Wang, W., Liu, C., Zhang, W., Wang, J., & Zhang, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1631316 · Cited by 3
Dashti, R., Safaei, F., Sadeghian, G., Hosseini, S. A., & Bani, M. S. (2025) · Journal of Biomaterials Applications · doi:10.1177/08853282251395196 · Cited by 4
Yang, J. Y., Kim, Y., An, S., Han, J. W., Choi, J., & Park, T. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311327 · Cited by 3
Atypical p38 Kinase Signaling in Retinal Vascular Damage and Recovery
Schulz, L., Young, A., Liu, F., Gattineni, S., Ghosh, S., Douglass, E. F., Kroeger, H., Narayanan, S. P., & Grimsey, N. J. (2025) · The FASEB Journal · doi:10.1096/fj.202503114r · Cited by 3
Chen, K. M., Chan, H.-C., & Chan, C.-M. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179034 · Cited by 3
Singh, A. K., Kolipaka, T., Pandey, G., Wagh, S. S., Samadder, B., & Srivastava, S. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108472 · Cited by 3
Li, Q., Zhou, X., Yang, Y., Zhang, Q., Li, Z., Han, H., Yuan, F., Deng, H., Lei, H., & Duan, Y. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.102817 · Cited by 5
Wang, Z., Chen, Y., Yang, L., Yao, D., & Shen, Y. (2023) · PeerJ · doi:10.7717/peerj.15643 · Cited by 3
Multi-Target Drug Strategies in the Treatment of Diabetic Retinopathy
Julius, A., Malakondaiah, S., Subbarayalu, R., Renuka, R. R., & Pothireddy, R. B. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-01936-x · Cited by 4
Moon, T. K., Kang, I. K., Lee, K. J., Kim, J. H., Kim, H. J., Han, A. R., Woo, H., Lee, J. Y., Choi, J., Park, K., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101404 · Cited by 2
Balas, M., Jhaveri, A., Khalid, F., Abdelaal, A., Popovic, M. M., Kertes, P. J., & Muni, R. H. (2025) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2025.05.014 · Cited by 2
Revolutionizing Diabetic Macular Edema Treatment: FDA Approval of Susvimo
Kumar, D., Gupta, V., Tanwar, R., & Jaiswal, N. K. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-01971-8 · Cited by 2
Melatonin Alleviates Retina Angiogenesis by Targeting Fibronectin and the VEGF Pathway
Chen, F., Yang, X., Yin, Y., Meng, Z., Wu, Z., Liu, D., Wu, C., Luo, J., & Wu, W. (2025) · The FASEB Journal · doi:10.1096/fj.202500814rr · Cited by 2
Intravitreal implants for drug delivery: clinical efficacy, safety, and translational perspectives
da Silva, C. N., Inoue, T. T., Dias, M. F., Fialho, S. L., & Silva‐Cunha, A. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2629545 · Cited by 2
Visual noise in augmented reality improves vision in age-related macular degeneration
Raul, P., Lee, T., Barry, R., Sabeti, F., & van Boxtel, J. J. A. (2026) · npj Aging · doi:10.1038/s41514-026-00389-3 · Cited by 2
Aptamer‐Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies
Best, N., Karabiyik, G., Geerling, G., Zwingelberg, S. B., Lang, G., & Humeník, M. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202505182 · Cited by 2
A Recent Update on Candidate Biomarkers in the Pathogenesis of Diabetic Retinopathy
Shakthiya, T., Chand, L., & Annamalai, R. (2025) · The Open Biomarkers Journal · doi:10.2174/0118753183372247250213110930 · Cited by 2
Udaipuria, N., & Bhattacharya, S. (2025) · International Journal of Polymeric Materials · doi:10.1080/00914037.2025.2558674 · Cited by 2
Deng, L., Wang, L., Meng, Y. F., Zheng, J., Dong, X., Chen, Y., & Huang, H. (2024) · Biochemistry Research International · doi:10.1155/bri/1405338 · Cited by 1
Tan, L., Linghu, W., Xu, M., Liu, S., Li, Y., Ke, Y., Pazo, E. E., & Ren, X. (2025) · Retina · doi:10.1097/iae.0000000000004384 · Cited by 1
Self-citationFerroni, M., Gaetano, F. D., Zonfrillo, M., Bono, N., Cereda, M. G., Pierimarchi, P., Sferrazza, G., Candiani, G., & Boschetti, F. (2025) · Biomedical Materials · doi:10.1088/1748-605x/adc21f · Cited by 1
Riaz, S., Khan, M. T., Chaudhry, Q. L., Chaudhry, S. L., & Munir, F. (2025) · Pakistan Journal of Ophthalmology · doi:10.36351/pjo.v41i3.1994 · Cited by 1
Future Directions for Receptor Tyrosine Kinases in Cancer Treatment
Sharma, A., Chakraborty, D., & Yadav, M. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-93894-8_12 · Cited by 3
Amatha, S., Das, R., Gautam, M. K., & Mondal, S. (2025) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2025.03.009 · Cited by 2
Chung, D. H., Jee, D., Roh, Y., Ra, H., Lee, M. Y., Won, J. Y., Shin, J. A., Jung, S. H., & Park, Y. (2026) · Scientific Reports · doi:10.1038/s41598-026-41488-1 · Cited by 1
Sun, N., Li, J., Wang, J., Wang, J., Chen, T., Wang, Y., Liu, C., Yang, Yao, T., Feng, H., et al. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.4.64 · Cited by 1
Vasa Vasorum—A Silent Enemy After EVAR: A Case Report and Review of the Literature
Prentzas, I., Leivaditis, V., Andrikopoulou, C., Nikolakopoulos, K. M., Papageorgopoulou, C. P., Tabaku, K., Stathopoulou, M. S., Papathanassiou, Z., Tsantrizos, P., Mulita, F., et al. (2026) · Clinics and Practice · doi:10.3390/clinpract16060117 · Cited by 1
Contreras-Salinas, H., Vázquez-Beltrán, J. C., García-Sánchez, G., Quirarte-Justo, S., Macías, S. D. C. G., & Rodríguez-Herrera, L. Y. (2026) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986261462682 · Cited by 1
Scerbatiuc, C. (2024) · Moldovan Journal of Health Sciences · doi:10.52645/mjhs.2024.2.08 · Cited by 1
Muz, Ö. E., Keskin, Ş., Kara, Y., Karaoğlu, Ş. A., & Keskin, M. (2024) · Uludağ Arıcılık Dergisi · doi:10.31467/uluaricilik.1465376 · Cited by 1
A potential innovative surrogate marker for hypoxic injury: Shehata marker of angiogenesis
Mohamed, S. A. (2025) · Heart Vessels and Transplantation · doi:10.24969/hvt.2024.540 · Cited by 1
Biotechnological novel drug delivery systems for age-related macular degeneration
Amatha, S., Das, R., Gautam, M. K., & Mondal, S. (2025) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2025.07.010 · Cited by 1
Current Challenges in the Management of Vitreoretinal Conditions
Panos, G. D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041171 · Cited by 1
Zhu, Y., Si, H., Li, W., Chen, X., Tao, M., Pan, J., Luo, Y., & Xiao, W. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5140915 · Cited by 1
Retinoprotective compounds, current efficacy, and future prospective
Marino, R., Sappington, R. M., & Feligioni, M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.373662
Nihei, A., Yamamoto, M., Hirayama, K., Kyo, A., Misawa, N., Kohno, T., & Honda, S. (2024) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2024.102078
The Impact of Potent Addictive Substances on Angiogenic Behavior: A Comprehensive Review
AL-Eitan, L. N., Alahmad, S. Z., & Khair, I. Y. (2024) · Current Neuropharmacology · doi:10.2174/1570159x23666240905125037
Specht, A., Klimezak, M., & Cambridge, S. B. (2025) · ChemMedChem · doi:10.1002/cmdc.202400827
Julius, A., Malakondaiah, S., Subbarayalu, R., & Pothireddy, R. B. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-01942-z
Bukke, A. K., Uma, G., Vairagyam, R., & Vontela, K. R. (2025) · Cureus · doi:10.7759/cureus.88475
Promlek, T., Wongsuk, T., Suraamornkul, S., & Chantarasorn, Y. (2025) · Ophthalmic Genetics · doi:10.1080/13816810.2025.2565636
Sharma, C., Chakraborty, M., Ali, M. H. J., Bhattarai, A., Acharjya, R., & Bhuyan, N. R. (2025) · Next research. · doi:10.1016/j.nexres.2025.100904 · Cited by 1
Exploring the role of P2X receptors in age-related macular degeneration
Youn, S. (2024) · cIRcle (University of British Columbia) · doi:10.14288/1.0442051
Jayadev, C., Talwar, D., Bhende, M., Narayanan, R., Gupta, V., Chakraborty, D., Deka, S., Manayath, G. J., & BANKER, A. S. (2026) · Cureus · doi:10.7759/cureus.100779
Pan, J.-Q., Chen, J., & Pan, X.-B. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153251
Recent advances of age-related macular degeneration (AMD) treatment enabled by nanomaterials
Li, X., Xu, L., Wu, H., Fang, H., & Tian, H. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.112445 · Cited by 1
Self-citationReal-Life-Daten der IVOM-Intervalle nach Umstellung auf Faricimab-Therapie
Muranyi, D. S., Molling, J., Hammer, U., Habermann, A., Lehmann, G., Luci, E., Buchwald, C., & Hammer, T. (2026) · Die Ophthalmologie · doi:10.1007/s00347-026-02389-w
Impact of Comorbid Hypertension and Diabetes on Anti‐VEGF Treatment Outcomes in Macular Edema
Lu, W., Yang, S., Zheng, C., & Wu, Z. (2026) · Journal of Ophthalmology · doi:10.1155/joph/8794635
An update on the port delivery system with ranibizumab for retinal diseases
Samman, M., Khan, H., Aziz, A. A., Patel, R., & Khanani, A. M. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2652029
How looking through static can help people with a common degenerative disease see better
Raul, P., & van Boxtel, J. J. A. (2026) · The Conversation · doi:10.64628/aa.44rysu469
Kwon, M., Kim, S., Lee, K., Song, J.-H., Lee, J., Kim, I., Min, J.-K., Kwon, Y.-G., Lee, D. G., Lee, N.-K., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08457-8
Pishgahzadeh, E., Mafakher, L., Dabirian, S., Vahidi, H., Kazemi‐Lomedasht, F., Jamshidi, H., & Mohit, E. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104432
Metadata
- Authors
- Xu, M., Fan, R., Fan, X., Shao, Y., & Li, X.
- Affiliations
- Tianjin Medical University Eye Hospital (CN)
- Corresponding author
- Li, Xiaorong
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-09
- Volume
- Volume 16
- Pages
- 3241-3262
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC9512290
- OpenAlex
- W4296720485
- Cited by
- 111
- References
- 145
- Citations by year
- 2026: 36 · 2025: 42 · 2024: 23 · 2023: 10
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (acceptedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Natural Science Foundation of China (82171085)
- Natural Science Foundation of Tianjin City (19JCZDJC64000)
- Tianjin Research Innovation Project for Postgraduate Students (2021YJSB271)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- VEGF inhibitors, sustained drug release, retinal angiogenesis, diabetic macular edema, age-related macular degeneration, intravitreal injection, ocular neovascular disease, drug encapsulation
- MeSH terms
- Bevacizumab, Ranibizumab, Delayed-Action Preparations, Diabetic Retinopathy, Humans, Macular Edema, Neovascularization, Pathologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.